Last reviewed · How we verify
Intravenous ImmuneGlobulin
Intravenous immunoglobulin (IVIG) provides passive immunity by delivering pooled antibodies from multiple donors to neutralize pathogens and modulate immune responses.
Intravenous immunoglobulin (IVIG) provides passive immunity by delivering pooled antibodies from multiple donors to neutralize pathogens and modulate immune responses. Used for Primary immunodeficiency disorders, Secondary immunodeficiency (e.g., in hematologic malignancies), Autoimmune conditions (e.g., immune thrombocytopenia, Guillain-Barré syndrome).
At a glance
| Generic name | Intravenous ImmuneGlobulin |
|---|---|
| Sponsor | University Health Network, Toronto |
| Drug class | Immunoglobulin replacement therapy / Immunomodulator |
| Target | Multiple (IgG antibodies, Fc receptors, complement system) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
IVIG is a blood product containing immunoglobulins (primarily IgG) extracted from the plasma of thousands of healthy donors. It works through multiple mechanisms: providing immediate passive antibody protection against infections, blocking pathogenic autoantibodies, modulating complement activation, and regulating T and B cell function. It is used both for immunodeficiency replacement and as an immunomodulatory agent in autoimmune and inflammatory conditions.
Approved indications
- Primary immunodeficiency disorders
- Secondary immunodeficiency (e.g., in hematologic malignancies)
- Autoimmune conditions (e.g., immune thrombocytopenia, Guillain-Barré syndrome)
- Chronic inflammatory demyelinating polyneuropathy (CIDP)
- Kawasaki disease
Common side effects
- Headache
- Fever
- Chills
- Myalgia
- Nausea
- Infusion reactions
- Aseptic meningitis
- Thromboembolism
- Acute kidney injury
Key clinical trials
- IVIg Therapy for Patients With Idiopathic Cardiomyopathy and Endomyocardial Biopsy Proven High PVB19 Viral Load (PHASE1)
- Intravenous Immune Globulin Treatment Compared to Placebo in Patients With Myasthenia Gravis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous ImmuneGlobulin CI brief — competitive landscape report
- Intravenous ImmuneGlobulin updates RSS · CI watch RSS
- University Health Network, Toronto portfolio CI